Chen Binglai
- Specjalizacja: Immunolog
- 20 lat doświadczenia
- Języki:Chinese
- Miejsce pracy: Chiny, Qionghai, 博鳌国际诊疗中心
- Led a technological innovation project, “Cancer Treatment Based on Cell Culture Technology,” supported by the Shanghai Pujiang Talent Program.
Dr. Chen Binglai is a biological immunology expert (MD). He holds a PhD in Medicine from Central South University, with a focus on genetics and integrated TCM and Western medicine. He completed postdoctoral training at New York University and the University of Bologna. He is a visiting professor at Zhongshan Hospital, Fudan University.
He is affiliated with the Shanghai Pujiang Talent Program and the Yangpu District 3310 Talent Program. He leads the innovation project “Cancer Treatment Based on Cell Culture Technology,” supported by the Pujiang Program.
He has years of oncology practice and extensive experience in treating malignant tumors. His work focuses on the clinical use and research of CAR-T, NK cell, and stem cell therapies. He uses the Lecheng pilot program to advance clinical translation in China and to offer personalized treatment plans.
Usługi lekarza
Jak Państwo oceniają naszą usługę?
Kwalifikacje
Hospital Expert - Chen Binglai (Biological Immunology Expert / MD)
PhD in Medicine and Genetics and Integrated Traditional Chinese and Western Medicine from Central South University
Postdoctoral Fellow at New York University and the University of Bologna
Shanghai Pujiang Talent Program and Yangpu District 3310 Talent Program
Visiting Professor at Zhongshan Hospital Affiliated to Fudan University
The project "Cancer Treatment Based on Cell Culture Technology," which he led, is classified as a technological innovation project and is supported by the Shanghai Pujiang Talent Program.
Areas of Expertise: Years of clinical experience in oncology, possessing extensive expertise in the comprehensive treatment of malignant tumors.
Focusing on the clinical application and research of new biotechnologies (including CAR-T cell therapy, NK cell therapy, and stem cell therapy).
Leveraging Lecheng's "pilot program" policy, promoting the clinical translation of cutting-edge international cell therapy technologies in China.
Skilled at combining basic research findings with clinical practice to provide patients with personalized treatment plans.
Mogą Państwa również zainteresować
Płatność i nagrody
Państwo nie płacą za nasze usługi
Płatność jest dokonywana bezpośrednio w klinice lub na jej oficjalne konto bankowe.
Niektóre kliniki mogą wymagać wpłaty depozytu zgodnie ze swoją polityką.
Proszę płacić w ratach.
Proszę zapraszać znajomych do Bookimed i otrzymywać nagrody.